News | December 16, 2021
Syngene extends contract with Amgen till 2026
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Doctors can now analyse their historical prescriptions within a few clicks enabling them to identify different cohorts of patients and the treatment given to them
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
FDA changes inspection classification of the facility to Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
